Evolution and Control of COVID-19 Epidemic in Hong Kong

Viruses. 2022 Nov 14;14(11):2519. doi: 10.3390/v14112519.

Abstract

Hong Kong SAR has adopted universal masking, social distancing, testing of all symptomatic and high-risk groups for isolation of confirmed cases in healthcare facilities, and quarantine of contacts as epidemiological control measures without city lockdown or border closure. These measures successfully suppressed the community transmission of pre-Omicron SARS-CoV-2 variants or lineages during the first to the fourth wave. No nosocomial SARS-CoV-2 infection was documented among healthcare workers in the first 300 days. The strategy of COVID-19 containment was adopted to provide additional time to achieve population immunity by vaccination. The near-zero COVID-19 situation for about 8 months in 2021 did not enable adequate immunization of the eligible population. A combination of factors was identified, especially population complacency associated with the low local COVID-19 activity, together with vaccine hesitancy. The importation of the highly transmissible Omicron variant kickstarted the fifth wave of COVID-19, which could no longer be controlled by our initial measures. The explosive fifth wave, which was partially contributed by vertical airborne transmission in high-rise residential buildings, resulted in over one million cases of infection. In this review, we summarize the epidemiology of COVID-19 and the infection control and public health measures against the importation and dissemination of SARS-CoV-2 until day 1000.

Keywords: COVID-19; SARS-CoV-2; infection control; variants.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Disease Outbreaks / prevention & control
  • Hong Kong / epidemiology
  • Humans
  • Infection Control
  • SARS-CoV-2*

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This study was supported by the Health and Medical Research Fund (HMRF) Commissioned Research on the Control of Infectious Disease (Phase IV), CID-HKU1-16, Health Bureau, Hong Kong Special Administrative Regional Government.